Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0SCLSY)
| ADC Name |
GB251
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
GB251; NBT828; GB221-vcMMAE
Click to Show/Hide
|
|||||
| Organization |
Genor Biopharma (Originator);NewCon Biotech
|
|||||
| Drug Status |
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
Anti-HER2 antibody
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (HER2)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Payload Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
BiM-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
| Special Approval(s) |
Special approval (NMPA)
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Indication | Phase 1 | Phase 2 | Phase 3 | Approved | ||
|---|---|---|---|---|---|---|
| Breast cancer |
1 Trials
|